Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Oral vs. intravenous busulfan pre-conditioning for HSCT

Marcos de Lima • 25 Oct 2019
COSTEM 2019
General Busulfan

Marcos de Lima, MD, University Hospitals Cleveland Medical Center, Cleveland, OH, talks on the main aims and methods of his study on the comparable results seen in oral versus intravenous busulfan in patients undergoing hematopoietic stem cell transplantation (HSCT), with the exception of earlier onset of mucositis, and goes on to share the initial findings of this study. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Marcos de Lima

1:08
Point-of-care CAR T-cells
Marcos de Lima • 26 Aug 2020
3:36
Results of a site-manufactured anti-CD19 CAR-T in nHL
Marcos de Lima • 31 Aug 2020
5:15
Outlook on the current CAR-T climate
Marcos de Lima • 1 Sep 2020
5:15
Outlook on the current CAR-T climate
Marcos de Lima • 27 Aug 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals